Cargando…

Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines

The lack of validated immunological correlates of protection makes tuberculosis vaccine development difficult and expensive. Using intradermal bacille Calmette-Guréin (BCG) as a surrogate for aerosol Mycobacterium tuberculosis (M.tb) in a controlled human infection model could facilitate vaccine dev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harris, Stephanie A., White, Andrew, Stockdale, Lisa, Tanner, Rachel, Sibley, Laura, Sarfas, Charlotte, Meyer, Joel, Peter, Jonathan, O'Shea, Matthew K., Manjaly Thomas, Zita-Rose, Hamidi, Ali, Satti, Iman, Dennis, Mike J., McShane, Helen, Sharpe, Sally
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Churchill Livingstone 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854371/ https://www.ncbi.nlm.nih.gov/pubmed/29523335 http://dx.doi.org/10.1016/j.tube.2017.11.006

Ejemplares similares

A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
por: Tanner, Rachel, et al.
Publicado: (2021)

The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
por: Tanner, Rachel, et al.
Publicado: (2021)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial
por: Satti, Iman, et al.
Publicado: (2014)

Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A
por: Harris, Stephanie A., et al.
Publicado: (2014)

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults
por: Sheehan, Sharon, et al.
Publicado: (2015)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
por: Minhinnick, Alice, et al.
Publicado: (2016)

Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
por: Harris, Stephanie A., et al.
Publicado: (2014)

Gene Expression and Cytokine Profile Correlate With Mycobacterial Growth in a Human BCG Challenge Model
por: Matsumiya, Magali, et al.
Publicado: (2015)

Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity
por: Minhinnick, Alice, et al.
Publicado: (2016)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults
por: Wilkie, Morven, et al.
Publicado: (2020)

T-cell activation is an immune correlate of risk in BCG vaccinated infants
por: Fletcher, Helen A., et al.
Publicado: (2016)

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants
por: Fletcher, Helen A., et al.
Publicado: (2016)

Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination
por: Bitencourt, Julia, et al.
Publicado: (2022)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
por: Manjaly Thomas, Zita-Rose, et al.
Publicado: (2019)

IV BCG Vaccination and Aerosol BCG Revaccination Induce Mycobacteria-Responsive γδ T Cells Associated with Protective Efficacy against M. tb Challenge
por: Morrison, Alexandra L., et al.
Publicado: (2023)

Aerosol immunisation for TB: matching route of vaccination to route of infection
por: Manjaly Thomas, Zita-Rose, et al.
Publicado: (2015)

Spore-FP1 tuberculosis mucosal vaccine candidate is highly protective in guinea pigs but fails to improve on BCG-conferred protection in non-human primates
por: White, Andrew D., et al.
Publicado: (2023)

Characterization of the Infant Immune System and the Influence and Immunogenicity of BCG Vaccination in Infant and Adult Rhesus Macaques
por: Sarfas, Charlotte, et al.
Publicado: (2021)

Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study
por: Wilkie, Morven, et al.
Publicado: (2022)

TB and SIV Coinfection; a Model for Evaluating Vaccine Strategies against TB Reactivation in Asian Origin Cynomolgus Macaques: A Pilot Study Using BCG Vaccination
por: White, Andrew D., et al.
Publicado: (2021)

Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations
por: Sharpe, S., et al.
Publicado: (2016)

Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infants
por: Satti, Iman, et al.
Publicado: (2022)

Using Data from Macaques To Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: a Proof-of-Concept Study of Immunostimulation/Immunodynamic Modeling Methods
por: Rhodes, Sophie J., et al.
Publicado: (2017)

Evaluation of the Immunogenicity of Mycobacterium bovis BCG Delivered by Aerosol to the Lungs of Macaques
por: White, A. D., et al.
Publicado: (2015)

The Humoral Immune Response to BCG Vaccination
por: Tanner, Rachel, et al.
Publicado: (2019)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery()
por: Meyer, Joel, et al.
Publicado: (2013)

Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response
por: Matsumiya, Magali, et al.
Publicado: (2014)

Protective Efficacy of Inhaled BCG Vaccination Against Ultra-Low Dose Aerosol M. tuberculosis Challenge in Rhesus Macaques
por: White, Andrew D., et al.
Publicado: (2020)

Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection
por: O’Shea, Matthew K., et al.
Publicado: (2018)

Editorial Commentary: Understanding BCG Is the Key to Improving It
por: McShane, Helen
Publicado: (2014)

Preclinical Development of an In Vivo BCG Challenge Model for Testing Candidate TB Vaccine Efficacy
por: Minassian, Angela M., et al.
Publicado: (2011)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial
por: Rowland, Rosalind, et al.
Publicado: (2013)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
por: Wajja, Anne, et al.
Publicado: (2017)

Cytomegalovirus infection is a risk factor for tuberculosis disease in infants
por: Müller, Julius, et al.
Publicado: (2019)

Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle
por: Villarreal-Ramos, Bernardo, et al.
Publicado: (2014)

Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection
por: Tanner, Rachel, et al.
Publicado: (2020)

High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation
por: Sibley, Laura, et al.
Publicado: (2021)

Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques
por: White, Andrew D., et al.
Publicado: (2022)

Differences in host immune populations between rhesus macaques and cynomolgus macaque subspecies in relation to susceptibility to Mycobacterium tuberculosis infection
por: Sibley, Laura, et al.
Publicado: (2021)

A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis
por: Zelmer, Andrea, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_oahqbu7h6oa262v915is6k895s